Pharmaceutical company Organon & Co. (NYSE: OGN) has reported higher revenues and adjusted earnings for the fourth quarter of 2023.
- Total revenue increased 8% annually to $1.60 billion in Q4, both on a reported basis and excluding the impact of foreign currency
- Women’s Health revenue increased 7% year-over-year, driven primarily by strong growth in Organon’s fertility products
- Biosimilar revenue jumped 49% from last year as reported, and 48% on an FX-adjusted basis in Q4
- Established Brands revenue rose 3%, despite the impacts of Volume-Based Procurement initiatives and a challenging operating environment in China
- Q4 net income more than doubled to $546 million or $2.13 per share in the three months ended December 2023
- On an adjusted basis, earnings moved up to $0.88 per share in Q4 from $0.81 per share last year
- At $449 million, fourth-quarter adjusted EBITDA was up 18% from the year-ago quarter.
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
INTU Earnings: Intuit Q3 2024 revenue and adj. profit top expectations
Intuit Inc. (NASDAQ: INTU) Thursday reported an increase in adjusted earnings and revenues for the third quarter of 2024. The results also exceeded analysts' estimates. At $6.74 billion, the Mountain
After blowout quarter, Nvidia (NVDA) looks set to continue riding the AI wave
Shares of NVIDIA Corporation (NASDAQ: NVDA) rallied this week after the semiconductor giant reported robust first-quarter numbers. Being a first mover in artificial intelligence chips, the company is spearheading the
Target Corp. (TGT): A brief look at the retailer’s performance in Q1 2024
Shares of Target Corporation (NYSE: TGT) rose over 1% on Thursday. The stock has dropped over 11% in the past one month. The company delivered mixed results for the first
